MDLinxTargeting the Cause, Not the Symptom: The New Paradigm in Pediatric Hearing Care

Gene therapy now restores hearing in OTOF-related deafness by correcting defective synaptic transmission, replacing lifelong cochlear implant dependence with physiologic function. Dual-AAV trials show hearing restoration within 30 days post-treatment, with speech perception gains in pediatric participants.

🏥 CLINICAL CONSIDERATIONS

• Genetic testing for OTOF mutations shifts from diagnostic to time-sensitive eligibility screening for gene therapy trials and emerging treatments
• Cochlear implant counseling now requires discussing gene therapy option before families commit to irreversible device-dependent pathway
• DFNB9 presents preserved hair cells with failed synaptic transmission, creating biologically accessible target for otoferlin restoration therapy
• Dual-AAV programs from Akouos and Regeneron report functional hearing restoration within 30 days, with speech perception improvements in most participants
• Universal genetic testing anticipated as treatment pathways expand beyond monogenic OTOF to other hereditary hearing loss etiologies

✅ PRACTICE APPLICATIONS

• Order genetic testing early when OTOF suspected to avoid missing treatment eligibility windows
• Discuss gene therapy option alongside cochlear implants during family counseling for DFNB9 cases
• Establish long-term audiology and speech-language tracking protocols to monitor therapy durability over years
• Explain outcomes using functional endpoints: spoken language, classroom function, localization, listening effort

More in Otolaryngology